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Abstract The trigeminal autonomic cephalalgias include
cluster headache, paroxysmal hemicrania, short-lasting unilat-
eral neuralgiform headache attacks, and hemicrania continua.
While the majority responds to conventional pharmacological
treatments, a small but significant proportion of patients are
intractable to these treatments. In these cases, alternative
choices for these patients include oral and injectable drugs,
lesional or resectional surgery, and neurostimulation. The
evidence base for conventional treatments is limited, and the
evidence for those used beyond convention is more so. At
present, the most evidence exists for nerve blocks, deep brain
stimulation, occipital nerve stimulation, sphenopalatine gan-
glion stimulation in chronic cluster headache, and microvas-
cular decompression of the trigeminal nerve in short-lasting
unilateral neuralgiform headache attacks.
Keywords Trigeminal autonomic cephalalgias .
Neurostimulation . Nerve blocks . Sphenopalatine ganglion
stimulation . Occipital nerve stimulation . Deep brain
stimulation
Introduction
Trigeminal autonomic cephalalgias (TACs) are primary head-
ache disorders characterized by unilateral head pain occurring
in association with ipsilateral cranial autonomic symptoms.
TACs include cluster headache (CH), paroxysmal hemicrania
(PH), and short-lasting unilateral neuralgiform headache at-
tacks [including both short-lasting unilateral neuralgiform
headache attacks with conjunctival injection and tearing
(SUNCT), and short-lasting unilateral headache attacks with
cranial autonomic symptoms (SUNA)], and hemicrania con-
tinua (HC) [1]. The clinical features of these attacks and their
response to medications are often distinctly characteristic
(Table 1).
The majority of patients will respond to standard or first-
line treatments, as outlined in international guidelines (Table 1)
[2]. A small, but highly disabled, group of patients will fail to
respond to these treatments, and this has led to the search for
alternative treatments.
Standard treatment recommendations for TACs are based
on moderate-to-low quality evidence, with little in the way of
randomized trials. These will not be covered in this article but
were recently reviewed by Pareja and Alvarez [3••]. Noncon-
ventional treatments are used on the basis of clinical experi-
ence and open-label series. The nonconventional treatments
currently in clinical use are reviewed here.
CH
CH consist of attacks of severe, strictly unilateral pain occur-
ring in the orbital, supraorbital and temporal regions, lasting
15–180 minutes, and that occur from once every other day to
eight times daily [1]. The pain is associated with autonomic
features and agitation (Table 1).
Acute Treatment
The conventional acute treatments for CH attacks are shown
in Table 1. When these fail, other options are scarce. Intranasal
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lidocaine has limited evidence [4], and subcutaneous
octreotide, a somatostain analogue, was found to be superior
to placebo in a single study [5]. Owing to practicalities of
administration, both have limited clinical usefulness.
Preventative Treatment
International guidelines give verapamil, lithium, methyser-
gide, topiramate, valproate, melatonin, and baclofen as first-
line treatments [2]. In their review, Pereja and Alvarez de-
scribe verapamil, lithium, and topiramate as being the stan-
dard treatments most commonly in use [3••]. Below, we shall
provide a summary of treatments aside from verapamil, lith-
ium, methysergide, and topiramate (Table 2).
Oral Treatments
Gabapentin is widely used in the treatment of pain and has
therefore been trialled in CHwith some highly positive data in
a limited series of patients. In the series of Leandri et al. [6], 12
patients undertook an open trial of gabapentin. All reported
freedom from pain after 8 days of treatment. Schuh-Hofer
et al. [7] used gapapentin as an adjunctive treatment in eight
patients with chronic CH (CCH) who had failed first-line
therapies. Six of eight patients reported a more than 50 %
reduction in attack frequency, with two claiming pain freedom
at the 4-months follow-up. Doses used by this group ranged
from 800 to 3600 mg. Long-term data on the use of
gabapentin do not exist, but Schuh-Hofer et al. [7] saw that,
over a year, follow-up patients did seem to develop tolerance.
Although the authors state that gabapentin is a well-tolerated
drug the dosage of which can be rapidly increased over a short
period of time, in clinical practice their highly positive rapid-
onset results have not been observed. It is relevant to note that
although gabapentin was previously considered beneficial for
migraine, both a placebo-controlled study by Silberstein et al.
[8] and recent Cochrane review have found no evidence of
efficacy [9].
Melatonin has been tried in CH, but there are contradictory
findings. Leone et al. [10] found a significant reduction in
headache frequency in their 2-week randomized placebo con-
trolled trial, with 5/10 patients with episodic CH (ECH) treat-
ed reporting cessation of their attacks after 5 days of treatment
(10 mg daily) but no effect on patients with CCH. Pringsheim
et al. [11] conducted a placebo-controlled crossover study
using 2 mg daily for 1 month in nine patients. They reported
no significant difference between melatonin and placebo.
Although conflicting evidence exists, melatonin makes for
an attractive therapy given its lack of side effects and drug
interactions. An argument can be made that the negative trial
group used a very low dose and, in practice, our unit recom-
mends a treatment dose of 12–16 mg daily. Further trials with
higher doses need to be carried out before clear recommenda-
tions can be made.
Table 1 Clinical features of the trigeminal autonomic cephalalgias and first-line treatments
Cluster headache Paroxysmal
hemicrania
Hemicrania
continua
Short-lasting unilateral
neuralgiform headache attacks
(SUNCT/SUNA)
ICHD-3 beta Code 3.1 3.2 3.4 3.3
SUNCT 3.3.1
SUNA 3.3.2
Sex (F:M) 1:5–7 1:1 2:1 1:2
Pain Type
Severity
Stabbing, boring
Severe
Throbbing, stabbing,
boring
Moderate–severe
Throbbing, ache, sharp, pressure
Moderate background with severe
exacerbations
Sharp, shooting, burning
Severe
Duration and frequency 15–180 mins, 1–8/day 2–30 mins, 5–40/day Continuous 1–600 s, 1–200/day
Autonomic features Yes Yes Yes with exacerbations Yesa
Indometacin effect No Complete resolution Complete resolution No
First choice abortive
agent
Injectable or nasal
sumatriptan
Oxygen
Nil Nil Nil
First choice preventative
agents
Verapamil
Lithium
Topiramate
Methysergideb
Indometacin Indometacin Lamotrigine
SUNCT short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing, SUNA short-lasting unilateral neuralgiform
headache attacks with autonomic symptoms, ICHD-3 beta International Classification of Headache Disorders 3rd edition Beta version, F female,Mmale
a SUNCT: both conjunctival injection and tearing; SUNA: only one or neither of conjunctival injection and tearing
bMethysergide is either not available or is due to be withdrawn in several countries
438, Page 2 of 13 Curr Pain Headache Rep (2014) 18:438
T
ab
le
2
Su
m
m
ar
y
of
ev
id
en
ce
fo
r
or
al
an
d
in
je
ct
ab
le
al
te
rn
at
iv
e
tr
ea
tm
en
ts
fo
r
cl
us
te
r
he
ad
ac
he
n
O
ut
co
m
e
D
os
in
g
de
ta
ils
G
ab
ap
en
tin
L
ea
nd
ri
et
al
.[
6]
,S
ch
uh
-H
of
er
et
al
.[
7]
20
(1
2
C
C
H
)
P
os
iti
ve
18
/2
0
80
0–
36
00
m
g
da
ily
M
el
at
on
in
L
eo
ne
et
al
.[
10
]
10
(t
re
at
m
en
tg
ro
up
;2
C
C
H
),
10
(p
la
ce
bo
gr
ou
p)
T
re
at
m
en
tg
ro
up
:p
os
iti
ve
5/
10
tr
ea
te
d
Pl
ac
eb
o
gr
ou
p:
po
si
tiv
e
0/
10
S
ig
ni
fi
ca
nt
di
ff
er
en
ce
to
pl
ac
eb
o
(p
<
0.
03
)
10
m
g
da
ily
Pr
in
gs
he
im
et
al
.[
11
]
9
(6
C
C
H
),
cr
os
so
ve
r
tr
ia
l
N
o
si
gn
if
ic
an
td
if
fe
re
nc
e
to
pl
ac
eb
o
(p
>
0.
05
)
2
m
g
da
ily
fo
r
1
m
on
th
,p
la
ce
bo
fo
r
on
e
m
on
th
B
ac
lo
fe
n
H
er
in
g-
H
an
it
et
al
.[
12
]
16
(E
C
H
)
Po
si
tiv
e
13
/1
6
15
–3
0
m
g
da
ily
V
al
pr
oi
c
ac
id
H
er
in
g
et
al
.[
13
]
15
(2
C
C
H
)
P
os
iti
ve
11
/1
5
60
0–
20
00
m
g
da
ily
E
lA
m
ra
ni
et
al
.[
14
]
50
(t
re
at
m
en
tg
ro
up
;1
1
C
C
H
),
46
(p
la
ce
bo
gr
ou
p;
6
C
C
H
)
T
re
at
m
en
tg
ro
up
:p
os
iti
ve
25
/5
0
Pl
ac
eb
o
gr
ou
p:
po
si
tiv
e
29
/5
0
N
o
si
gn
if
ic
an
td
if
fe
re
nc
e
to
pl
ac
eb
o
(p
=
0.
23
)
1–
2
g
da
ily
C
an
de
sa
rt
an
T
ro
nv
ik
et
al
.[
15
]
24
(t
re
at
m
en
tg
ro
up
),
16
(p
la
ce
bo
gr
ou
p)
N
o
si
gn
if
ic
an
td
if
fe
re
nc
e
to
pl
ac
eb
o
fo
r
ch
an
ge
in
at
ta
ck
fr
eq
ue
nc
y
(p
=
0.
38
).
P
os
th
oc
an
al
ys
is
si
gn
if
ic
an
td
if
fe
re
nc
e
to
pl
ac
eb
o
(p
<
0.
01
,R
R
1.
3)
32
m
g
da
ily
L
ev
itr
ac
et
am
Pa
le
rm
o
et
al
.[
16
]
2
2
1–
2
g
(u
np
ub
lis
he
d
da
ta
on
fu
rt
he
r
3
C
C
H
re
sp
on
di
ng
)
B
ot
ul
in
um
to
xi
n
So
st
ak
et
al
.[
17
],
R
ob
bi
ns
[1
8]
,
Fr
eu
nd
an
d
S
ch
w
ar
tz
[1
9]
,S
m
ut
s
an
d
B
ar
na
rd
[2
0]
24
(1
5
C
C
H
)
P
os
iti
ve
11
/2
4
24
–5
0
un
its
N
er
ve
bl
oc
ks
G
O
N
L
eu
ro
x
et
al
.[
22
•]
21
(t
re
at
m
en
tg
ro
up
;7
C
C
H
),
22
(p
la
ce
bo
gr
ou
p;
8
C
C
H
)
Si
gn
if
ic
an
td
if
fe
re
nc
e
be
tw
ee
n
gr
ou
ps
in
m
ea
n
no
at
ta
ck
s
a
da
y
un
til
da
y
15
(p
<
0.
01
)
N
o
si
gn
if
ic
an
td
if
fe
re
nc
e
be
tw
ee
n
gr
ou
ps
re
ac
hi
ng
50
%
re
du
ct
io
n
of
at
ta
ck
s
at
15
da
ys
(p
=
0.
06
)
T
re
at
m
en
t:
3.
75
m
g
co
rt
iv
az
ol
,3
in
je
ct
io
ns
gi
ve
n
48
–7
2
h
ap
ar
t
Pl
ac
eb
o:
sa
lin
e
A
m
br
os
in
ie
ta
l.
[2
3•
]
13
(t
re
at
m
en
tg
ro
up
;4
C
C
H
),
10
(p
la
ce
bo
gr
ou
p;
3
C
C
H
)
T
re
at
m
en
tg
ro
up
:p
os
iti
ve
11
/1
3
(4
C
C
H
)
Pl
ac
eb
o
gr
ou
p:
po
si
tiv
e
0/
10
S
ig
ni
fi
ca
nt
di
ff
er
en
ce
be
tw
ee
n
gr
ou
ps
(p
<
0.
01
)
T
re
at
m
en
t:
be
ta
m
et
ha
so
ne
an
d
xy
lo
ca
in
e
Pl
ac
eb
o:
sa
lin
e
an
d
xy
lo
ca
in
e
L
am
br
u
et
al
.[
83
]
83
(8
3
C
C
H
)
P
os
iti
ve
47
/8
3
(f
ir
st
in
je
ct
io
n)
,3
1/
37
(s
ec
on
d
in
je
ct
io
n)
,2
7/
28
(t
hi
rd
in
je
ct
io
n)
80
m
g
m
et
hy
lp
re
dn
is
ol
on
e
an
d
lid
oc
ai
ne
S
P
G
Curr Pain Headache Rep (2014) 18:438 Page 3 of 13, 438
Baclofen has gamma-aminobutyric acid-ergic actions and
is used in a variety of nonheadache-related pain conditions. Its
use in CH has been evaluated by Hering-Hanit and Gadoth
[12] in an open-label series of 16 patients with ECH. Patients
were treated with a 15–30 mg daily dose of baclofen for a
3-week period. Twelve of the 16 patients reported that their
attacks ceased within a week of starting treatment, and one
more reported pain freedom by week two. No side effects
were reported and the drug seemed to retain its efficacy on
repeated use. Tizanadine, an alpha-2 adrenergic agonist, has
similar antinociception actions to baclofen in other conditions
but is better tolerated. There is no published evidence of its
usefulness in CH but our local experience is of a similar
efficacy to baclofen. Again, randomized controlled trials are
indicated on both drugs.
Valproic acid (valproate) is a drug used in the treatment
of migraine and it has also been evaluated in three reports
on CH treatment. Hering and Kuritzky [13] conducted an
open-label study on 15 patients using 600 mg–2 g daily
of valproate taken until the expected end of their bout
(from 2 weeks to 2 months). Eleven patients reacted
favorably to treatment; nine were rendered pain free
[13]. Although patients reported typical bouts lasting many
weeks, there is a possibility that spontaneous remission
accounted for the positive response seen in the group.
Therefore, El Amrani et al. [14] did a multicenter,
double-blind, placebo-controlled study of 96 patients given
1–2 g/day of sodium valproate for a 2-week treatment
period. No difference was observed between the placebo
and treatment groups. The response rate in the placebo group
was high (62 %), and authors state that this was likely to be
due to spontaneous remission and influenced their ability to
draw conclusions about the efficacy of the valproate [14].
Until further large-scale, randomized studies are conducted,
the use of valproate in CH is questionable.
Candesartan was investigated by Tronvik et al. [15]
in a placebo-controlled, multicenter study. Forty patients
with ECH were enrolled but the trial was negative [15].
Given that post hoc analysis showed a difference in the
number of attacks in the treatment group, larger studies
may prove useful.
Levetiracetam is an antiepileptic drug used for partial and
generalized seizures. It has been trialed in neuropathic pain
and migraine, with low-quality evidence suggesting its use-
fulness in both conditions. Recently, Palermo et al. [16] re-
ported two cases of ECH with attacks lasting several months
responding to 1 g daily of levetiracetam given for a 4-month
period. Both patients were pain free within a week and
remained so 6–8 months following discontinuation of the
drug. The same group also reported unpublished data of three
patients with CCH responding to 2 g daily of levetiracetam.
Our local experience is positive, with 3/5 patients treated over
the last 6 months responding well, and two failing to respondTa
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owing to an inability to tolerate the drug’s side effects of
apparent weight gain and worsening of headaches (unpub-
lished data). Overall, the drug has a very good side effect
profile and a low potential for interactions. Although the
mechanism of action is unclear, initial open-label data are
promising; however, further randomized controlled data are
clearly needed.
Injectable Treatments
Botulinum toxin has been reported to relieve pain in a number
of conditions, including headache, and has a licence for use in
chronic migraine in the USA and Europe. Only one open-label
study has looked at the effect of botulinum toxin in CH. In this
study, Sostak et al. [17] treated 12 patients with CH (9 with
CCH) with a total of 50 units injected into the temporalis,
frontalis, splenium capitis, and trapezius ipsilateral to the
headache. A reduction in attack frequency was seen by 3/12
patients, all with CCH, with a response lasting 2–3 months
postinjection. Case reports exist in abstract form for 12 pa-
tients. These patients were injected with 24–50 units into the
temporalis and frontalis muscles [18–20]. Eight patients are
reported to have had an improvement, with four patients with
ECH having abrupt cessation of their attacks. Although botu-
linum toxin is an attractive treatment option owing to its
potential long action, lack of side effects, and drug interac-
tions, further controlled trials similar to those done in chronic
migraine are essential.
Nerve Blocks
Transitional treatments are required when trying to gain rapid
control of attacks either during a short bout or until a preven-
tative agent takes effect. The standard option is oral cortico-
steroids but these should be prescribed with caution (in our
unit a maximum of twice a year) owing to the risk of side
effects with prolonged or frequent use. The alternative treat-
ment option is peripheral nerve blockade using local anes-
thetics, often in combination with corticosteroids.
Occipital nerve blocks are the most widely used and eval-
uated nerve block in the treatment of headache. The greater
(GONB) and lesser occipital nerve blocks have been targeted
owing to the physiological connections between the upper
cervical nerves and the trigeminal nerves in the
trigeminocervical complex. The majority of publications are
of case reports or observational studies. The most recent of
these, by Lambru et al. [21], looked at the efficacy of GONB
in CCH and found that after the first injection of methylpred-
nisolone and lidocaine, 57 % of patients reported a beneficial
response lasting, on average, 21 days. These results were
reproduced on repeated injections. Transient worsening of
headaches was seen in 6 % of patients.
Two groups have published prospective placebo controlled
data. Leroux et al. [22•] randomly allocated 43 patients (15
CCH, 28 ECH) to treatment with three suboccipital injections
of steroid given over 72 h or placebo. A significant difference
was found between treatment groups in the number of attacks
post-treatment, in the time taken to remission, and in patient
satisfaction with treatment [22•]. A reduction in the dose of
additional verapamil and rescue medication taken was also
seen. Ambrosini et al. [23•] conducted a blinded placebo-
controlled trial on 23 patients. A single injection of
suboccipital steroid led to complete attack suppression in
80 % of patients, with remission lasting at least 4 weeks.
Safety data on GONB are, on the whole, favorable; how-
ever, it is as yet unclear as to whether the blocks are better
given as a series or a single injection. In the routine clinic
setting it is often difficult to organize repeated injections, and
larger studies would be needed to change the current practice
of single injections.
Other sites used for nerve blocks include supraorbital,
auriculotemporal and supratrochler blocks, although no con-
trolled evidence exists for their use. Sphenopalatine ganglion
(SPG) blockades have been used to terminate CH since the
early 1900s but are clinically difficult to perform. Devoghel
[24] published a series of 120 blocks and reported a response
rate of 85 %. Pipolo et al. [25] reported a series of 15 patients
undergoing endoscopic SPG block for CH in which 54 %
experienced complete remission for between 1 and 28months.
Although not widely used, this and the increasingly positive
data emerging from SPG stimulation, may mean that SPG
blocks should be considered as part of the treatment arsenal
for refractive patients.
Resectional and Ablative Surgery
The disabling nature of CH has led many surgeons to target
the trigeminal nerve in a bid for pain control. Trigeminal nerve
root section was the traditional option for refractory CCH
prior to the advent of neuromodulation. Jarrar et al. [26]
reported that 76 % of their 17 patients with CCH experienced
long-term full or near complete pain relief. However, adverse
effects were dramatic, with one death, cerebrospinal fluid
leaks, and a case of meningitis. Another widely reported
adverse outcome of this type of surgery is corneal anesthesia;
in the series of Jarrar et al., two patients needed surgery for this
complication in order to prevent blindness. Other groups have
reported negative outcomes with CH continuing after trigem-
inal nerve root section [27].
Kano et al. [28] reviewed stereotactic Gamma knife radio-
surgery of the trigeminal and SPG for CCH in 2011 and
concluded that Gamma knife for CCH was a minimally inva-
sive and potentially attractive alternative to nerve root section,
with 60 % of patients reporting long-lasting pain relief. How-
ever, they found that CCH patients were far more likely to
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suffer facial sensory disturbances postoperatively than those
with trigeminal neuralgia (50 % compared with 10 %) [28]. A
similar review by McClelland et al. [29] was less positive,
finding that any initial benefit regressed with time, leaving
none of their nine patients reporting >50 % improvement by
2 weeks–2 years post-treatment, with 50 % of patients suffer-
ing some trigeminal nerve dysfunction as a consequence of
surgery. However promising the immediate results of trigem-
inal nerve surgery may appear, the adverse effects and long-
term outcomes are consis tent ly poor, and with
neuromodulation producing favorable results in terms of safe-
ty and follow-up, this sort of surgery should very much be at
the bottom of any treatment list, if conducted at all.
Neurostimulation
Occipital nerve stimulation (ONS) is a nondestructive surgical
option for refractory CCHwith an increasing evidence base of
open-label studies. Burns et al. [30•] first examined the role of
ONS in CCH in a series of 14 patients. Ten reported benefit,
three a benefit of >90 %, and three of >40 %. Magis et al. [31]
followed up 14 patients over an average of 37 months and
reported 11 to be receiving an at least 90 % reduction in
attacks. From these and other series available, ONS appears
to be safe, with the most frequent adverse effects reported
being dependent on surgical experience and battery depletion,
which is overcome by the introduction of rechargeable batte-
ries. A number of series report a side-shift in attacks if unilat-
eral stimulation is employed, and so bilateral lead placement is
now standard. A review of the current literature on ONS is
given by Magis and Schoenen [32••].
The SPG has also been a target for neuromodulation owing
to its links with the trigeminovascular system. Ansarinia et al.
[33] investigated SPG stimulation in six patients and found
that complete resolution of pain was seen within 3 mins in 11/
18 attacks treated. A larger, multicenter, sham-controlled
study was published in 2013 on the use of on-demand SPG
stimulation. A novel device was implanted in 28 patients who
randomly received full, sham, or subperception stimulation.
There was a significant difference in the number of resolving
attacks in the treated group. Sixty eight percent of treated
patients had clinically significant resolution of attacks. Ad-
verse events were mild, with 81 % reporting transient facial
sensory disturbance and only five cases requiring surgical
revision for lead migration or explanation [34••]. Unexpect-
edly, many patients demonstrated a reduction in attack fre-
quency following regular use of SPG stimulation despite the
study being designed to treat acute attacks. Further work is
ongoing into the prophylactic efficacy of SPG stimulation.
Deep brain stimulation (DBS) in CCH stems from imaging
findings showing the posterior hypothalamus becoming over-
active in attacks [35]. Leone et al. [36] reported the first case in
2001, and there are now >60 published cases. A recent review
of DBS was included in the review by Magis and Schoenen
[32••]. The overall clinical success rate is around 66 % (mean
follow-up 2 years) with a mean delay to clinical result of
42 days. The only placebo-controlled trial of DBS randomized
11 patients to active or sham stimulation for 2 months. No
difference was found between groups [37], but, given the
findings of other series of time delays to response of 1–
86 days, this is thought likely to be due to the short treatment
phase. The most commonly reported adverse effects are tran-
sient dizziness and visual disturbance associated with ampli-
tude changes.
However, DBS is not without serious risk, with one patient
dying from intracerebral hemorrhage postoperatively [38].
With collated data on DBS for CCH the risk for serious
hemorrhage is 3 %, which is within the range reported for
DBS for movement disorders [32••]. Owing to the risks of
surgery and lack of controlled evidence, the European Head-
ache Federation has reviewed the use of neuromodulation in
CCH. It has recommended that procedures should only be
considered when all other medical treatments have failed,
should be carried out by tertiary headache centers, and should
start with the least invasive methods before considering DBS
[39].
PH
PH is characterized by attacks of severe, strictly unilateral pain
occurring in the orbital or temporal regions that last for 2–
30 minutes and occur several or many times a day accompa-
nied by autonomic symptoms. The condition responds
completely to indometacin (Table 1) [1].
Acute medications are often of little use in this condition as
the attacks are too short lasting for any to take effect.
Preventative Medication
Oral Drugs
By definition, PH must show an absolute response to
indometacin and the diagnosis reconsidered if this response
is not seen [1]. Likewise, any patient requiring escalating
doses or suddenly becoming unresponsive to indometacin
should be reviewed for other pathology. The main reason to
use alternative treatments in this condition is the poor tolera-
bility of long-term indometacin, with 30 % of patients devel-
oping gastrointestinal (GI) side effects (Table 3) [40].
Cyclooxygenase (COX)-2 inhibitors are reported to have a
lower rate of GI side effects but should still be used with
caution in those with peptic ulcer disease. Case series from
two groups have shown some efficacy using celecoxib and
rofecoxib [41, 42]. Case reports also support the use of
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topiramate, with two patients reporting continued remission
after 2 years [43, 44]. Calcium channel blockers have also
been trialed in open-label series. Verapamil was found by
Evers and Husstedt [45] to have a mild-to-moderate effect,
and flunarazine induced complete remission in the five pa-
tients treated by Coria et al. [46], with no reported side effects.
Table 3 Summary of evidence for oral and injectable alternative treatments for paroxysmal hemicrania (PH) and hemicrania continua (HC\0
n Outcome Dosing details
PH
COX-2 inhibitors
Celecoxib
Mathew et al. [41] 1 Positive with 3-month follow-up 400 mg daily
Rofecoxib
Lisotto et al. [42] 2 Positive 2/2 with 8–14-month
follow-up
25–50 mg daily
Topiramate
Cohen et al. [43], Camarda et al. [44] 2 Positive with 6-month–2-year
follow-up
25–200 mg daily
Verapamil
Evers et al. [45] 10 Positive 4/10 Maximum 320 mg daily
Flunarazine
Coria et al. [46] 5 Positive 5/5 with 6-month follow-up
Nerve blocks
GON
Rossi et al. [47] 1 Positive to 5 injections over
20 months
Methylprednisolone and lidocaine
GON, LON, or SON
Antonaci et al. [48] 6 Negative in all Lidocaine
HC
COX-2 inhibitors
Rofecoxib
Peres et al. [52], Muller et al. [51] 10 Positive 4/9 25–50 mg daily
Celcoxib
Peres et al. [52] 5 Positive 4/5 800 mg daily
Melatonin
Rozen [53], Spears [54], Hollingworth
et al. [55]
5 (1 patient not trial
indometacin)
Positive 5/5 with 3–5-month
follow-up
9–15 mg daily
Topiramate
Camarda et al. [44], Matharu et al. [56],
Brighna et al. [57], Prakash et al. [58]
6 Positive with follow-up of 6 weeks–
1 year
100–200 mg daily
Verapamil
Rozen [59], Rajabally and Jacob [60] 2 Positive with follow-up of
8–9 months
120–480 mg daily
Gabapentin
Prakesh et al. [58], Moura et al. [61],
Spears [62]
12 Positive 10/12 with 2–13-month
follow-up
600–3600 mg daily
Nerve blocks
SON, trochlear, GON, LON
Guerrero et al. [63] 9 Positive 9/9
(5/9 pain free)
Bupivacaine, mepivacane, or
triamcinolone
GON, LON, or SON
Antonaci et al. [48] 7 at each site Positive 4/7 SON, negative GON
and LON
Lidocaine
Botulinum toxin
Khali et al. [64], Garza and Cutrer [65] 2 Positive over 3–4 injection cycles 100–155 units
COX-2 cyclooxygenase 2, GON greater occipital nerve, LON lesser occipital nerve, SON supraorbital nerve
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Nerve Blocks
The use of GON blocks in PH is supported by a single case
report by Rossi et al. [47]. Antonaci et al. [48] conducted
blocks of the greater occipital, lesser occipital, and supraor-
bital nerves in six patients with chronic PH with a negative
effect in all. Despite the limited evidence, GON blocks are
widely employed in headache clinics for PH with some suc-
cess. Obviously, larger studies are needed to support this
practice.
Neurostimulation
Once again, there is very little published evidence on the use
of neurostimulation for PH. No reports exist for the use of
ONS in PH; however, our local experience is that it may be
useful in refractory patients (unpublished data).
Walcott et al. [49] have published a single case of DBS in
PH. The patient had an immediate and complete response to
DBS, with the pain returning within hours after stoppingDBS.
With a follow-up period of 2 years, the device had retained its
efficacy. On the basis of such limited evidence,
neurostimulation should only be considered in patients who
have failed all possible medical treatments mentioned above.
HC
It is only recently that HC has been classified as a TAC,
having previously been considered a separate primary head-
ache disorder. The disorder is characterized by persistent,
strictly unilateral head pain associated with autonomic fea-
tures, and that is completely responsive to indometacin (Ta-
ble 1) [1].
Acute medications, including oxygen and triptans, have
generally been reported to be of little use in this condition
[50].
Preventative Treatments
Oral Treatments
By definition, HC must show a complete response to
indometacin and the diagnosis reconsidered if this is not seen.
The poor tolerability of indometacin is the main reason alter-
natives are sought (Table 3).
Once again, the evidence is limited to case reports, but oral
drugs that may prove useful include COX-2 inhibitors
(Rofecoxib and Celecoxib) [51, 52], melatonin [53–55],
topiramate [44, 56–58], verapamil [59, 60], and gabapentin
[58, 61, 62].
Injectable Treatments
The use of nerve blocks in HC is supported by two case series
using multiple cranial nerve blocks. Guerrero et al. [63] used
combinations of supraorbital, trochlear, and greater and lesser
occipital nerve blocks with good effect, and Antonaci et al.
[48] suggested that the positive response of HC to supraorbital
nerve blocks could be used to differentiate it from PH.
Antonaci et al. [48] found that GONBs were ineffective in
their patient group; however, in our experience, patients often
respond well and our practice is to offer this treatment.
Limited case reports exist for the efficacy of botulinum
toxin in HC [64, 65]. However, our local experience of good
results in 5/7 patients suggests that it can be useful and should
be considered in resistant cases (unpublished data).
Neurostimulation
There are three case series and reports of neuromodulation in
HC. Burns et al. [66] and Schwedt et al. [67] implanted a
BION device in a total of seven patients, with five reporting
>50 % improvement. Schwedt et al. [68] also included two
HC patients in their series of 15 ONS implantations and
although individual results for this headache type is not given
in the paper, the group quote a mean reduction of headache
frequency of one-third across the series.
Short-Lasting Unilateral Neuralgiform Headache Attacks
These conditions consist of attacks of moderate or severe,
strictly unilateral head pain lasting seconds to minutes, which
occur at least once a day and are usually associated with
prominent lacrimation and redness of the ipsilateral eye [1].
Two subtypes are recognized in the International Classifica-
tion for Headache Disorders-3 beta: SUNCT and SUNA. The
differentiation is made on the associated autonomic features;
patients with SUNCT exhibit both conjunctival injection and
tearing, whereas patients with SUNA will have only one or
neither of them (Table 1). Attacks are so brief that acute
medication is of little use to patients.
Preventative Medication
Oral Treatments
Current guidelines for the preventative treatment of short-
lasting unilateral neuralgiform headache attacks advise first-
line treatment with lamotrigine [2, 69]. Other oral therapies,
including topiramate, gabapentin, oxcarbazepine, carbamaze-
pine, and mexiletine all have case reports to support their use
as alternative agents (Table 4).
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Kuhn et al. [70], Matharu et al. [71], and Rossi et al. [72]
have reported a total of four patients achieving freedom from
pain on low doses of topiramate. Our experience is that higher
doses are often required to gain control of the condition.
Gabapentin has been reported in one open-label study and
three case reports to be efficacious in short-lasting unilateral
neuralgiform headache attacks. The open-label study conduct-
ed by Etemadifar et al. [73] consisted of eight patients all who
responded well, with five becoming pain free on 600mg daily.
Carbamazepine is first-line treatment for trigeminal neural-
gia, and given the clinical similarities and high misdiagnosis
rates between conditions a number of patients have been
trialed successfully on the drug in the clinical setting. Matharu
et al. [74] reviewed 33 patients given carbamazepine. Twenty-
two had no response and only three patients reported a com-
plete response to carbamazepine either alone or in combina-
tion with other drugs. Oxcarbazepine, a structural derivative
of carbamazepine, is a drug we frequently use locally for
short-lasting unilateral neuralgiform headache attacks as it
appears to be well tolerated and as efficacious as carbamaze-
pine. However, only two case reports exist in the literature to
support its use [75, 76].
Injectable Treatments and Nerve Blocks
Intravenous lidocaine is a useful agent in the treatment of
severe attacks or short-lasting unilateral neuralgiform
headache attack status. Matharu et al. [77] reported a series
of four intractable patients rendered pain free by the infusion.
The use of lidocaine and mexiletine, both antiarrthmyic drugs
acting on sodium channels, are reviewed in a paper by
Marmura [78].
Limited reports exist on the use of botulinum toxin and
GONB for short-lasting unilateral neuralgiform headache at-
tacks [79–81]. Our local experience is that GONB can be
useful in a small subset of patients.
Resectional and Ablative Surgery
A number of procedures have been conducted over the years,
often under the misdiagnosis of trigeminal neuralgia, includ-
ing microvascular decompression, glycerol rhizotomy, tri-
geminal nerve radiofrequency ablation, balloon compression
of the Gasserion ganglion, and Gamma knife therapy. Out-
comes are mixed but, in general, the adverse effects outweigh
any benefit. The one procedure that has appeared in recent
reviews to be efficacious, even with long-term follow-up, is
microvascular decompression (MVD) of the trigeminal nerve.
An Australian group found 19 patients described in the liter-
ature undergoing MVD. After a 14-month follow-up, 63 %
had complete resolution of pain and the rest had little or no
change. Adverse effects included wound infection, vertigo,
and jaw pain, and more serious effects of persistent hearing
loss and ataxia [82••]. Larger patient numbers and follow-up
Table 4 Summary of evidence for oral and injectable alternative treatments for short-lasting unilateral neuralgiform headache attacks
n Outcome Dosing details
Topiramate
Kuhn et al. [70], Matharu et al. [71], Rossi et al. [72] 4 Positive 4/4 with follow-up of 5–9 months 50–200 mg daily
Gabapentin
Etemadifar et al. [73] 8 Positive 8/8
(5 pain free)
600–900 mg daily
Carbamazepine
Matharu et al. [74]a 33 Complete or partial response 11/33 (alone or combination) 600–3000 mg daily
Oxcarbazepine
Marziniak et al. [75], Dora [76] 2 Positive 2/2 with follow up 1–36 months 600 mg daily
Intravenous lidocaine
Matharu et al. [77] 4 Positive 4/4 1–3 mg/min
Botulinum toxin
Zabalza [79] 1 Positive after 3 years of 3-monthly injections Injections around orbit
Nerve blocks
GON
Porta-Essam et al. [80] 1 Positive Bupivacaine
Pareja et al. [81] 3 Negative Lidocaine
SON
Pareja et al. [81] 7 Negative Lidocaine
GON greater occipital nerve, SON supraorbital nerve
a Review article
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periods are needed, but MVD appears a sensible option in
refractory patients with an aberrant vessel on imaging before
attempting neuromodulation, which is more expensive and
invasive.
Neurostimulation
A case series of nine patients undergoing ONS for SUNCT/
SUNA was reported by Lambru et al. [83], with eight
reporting a positive response and four freedom from pain.
Supraorbital and supratrochlear stimulation has also been
successful in one patient [84].
The outcomes of DBS for SUNCT appear promising, with
three patients gaining substantial relief within a fewmonths of
surgery [85–88]. Our own data consist of 5/6 patients treated
responding well, with two achieving freedom from pain [89].
Conclusion
CH, PH, HC, and short-lasting unilateral neuralgiform head-
ache attacks are well-defined stereotyped syndromes that can
be differentiated by their clinical features and treatment re-
sponses. Whilst each syndrome has standard treatment op-
tions, there will be a small but disabled group of patients who
will be unresponsive to these and require alternative agents.
The evidence base for any of these alternative treatments is
poor, but a wide variety of oral, injectable, and surgical
options does exist. Table 5 summarizes the alternative options
used in our clinic. Surgical techniques should be reserved for
patients proving intractable to all available medical treatments
and, with the exception of SUNCT/SUNA treated with MVD,
neurostimulation techniques will be the choice in the future.
One treatment that should potentially be made more widely
available to TAC patients is GONB. On the basis of highly
positive CH data, the favorable safety profile, and the ease of
the procedure, a strong argument can be made for using nerve
blocks earlier in the treatment regime or as a bridging therapy
in many more patients.
Currently, the most robust evidence exists for the treatment
of CH with the use of GONB, SPG stimulation, and melato-
nin. DBS appears promising but this is on the basis of increas-
ing numbers of case reports only. It is clear that large random-
ized trials are needed on all TAC treatments to allow guide-
lines to be based on efficacy and safety.
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